Related Experiment Video
Updated: Jul 1, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
265
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms
Justine Gantzer1, Maud Toulmonde2, François Severac3
1Department of Medical Oncology, Institut de Cancérologie de Strasbourg-Europe, Strasbourg, France.
Cancer
|March 12, 2024
Summary
A new PEComa prognostic score (PEC-PRO) reliably predicts recurrence risk in localized PEComa patients. This tool can improve follow-up strategies for these rare mesenchymal tumors.
Area of Science:
- Oncology
- Pathology
- Surgical Oncology
Background:
- Perivascular epithelioid cell neoplasms (PEComas) are a diverse group of mesenchymal tumors.
- Previous methods to distinguish benign from malignant PEComas lacked prognostic accuracy.
Purpose of the Study:
- To develop a reliable prognostic risk model for localized PEComa.
- To identify key clinicopathologic features impacting event-free survival (EFS).
Main Methods:
- Retrospective analysis of clinicopathologic data from 87 localized PEComa patients.
- Multivariate Cox proportional hazard model to derive the PEComa prognostic score (PEC-PRO).
- Risk stratification into low, intermediate, and high-risk groups based on PEC-PRO.
Main Results:
- The PEC-PRO score was developed, incorporating factors like positive surgical margins, necrosis, and male sex.
- Patients with high-risk PEC-PRO scores had significantly lower 2-year EFS rates (2.3%) compared to low-risk (93.7%).
- The Folpe classification did not correlate with EFS.
Conclusions:
- The PEC-PRO score effectively predicts postoperative recurrence risk in localized PEComa.
- This score can enhance patient follow-up strategies.
- Prospective validation of the PEC-PRO score is recommended.
